Magnetic resonance imaging (MRI) is superior to mammography alone in diagnosing intraductal components of invasive breast cancer, allowing more accurate mapping before breast conservation surgery, said Simone Schrading, MD, Department of Radiology, University of Bonn, Germany.
Magnetic resonance imaging (MRI) is superior to mammography alone in diagnosing intraductal components of invasive breast cancer, allowing more accurate mapping before breast conservation surgery, said Simone Schrading, MD, Department of Radiology, University of Bonn, Germany.
Dr Schrading's study included 139 women (mean age, 54 y) who had invasive breast cancer with additional intraductal components. All women underwent bilateral mammography and high-resolution bilateral breast MRI.
The overall sensitivity for identifying intraductal components was 85% for MRI and 37% for mammography alone. Thirty-four percent of intraductal components were identified by both imaging modalities. In 3%, only mammography was positive (false negative with MRI) and in 51%, only MRI was positive (false negative with mammography). Twelve percent of intraductal components were not identified by either imaging test.
By combining mammography and MRI, 88% of intraductal components were identified.
The sensitivity of MRI was independent of breast density. In American College of Radiology (ACR) type 1 breast tissue (lowest density), the sensitivity of MRI was 83%. In ACR 2, ACR 3, and ACR 4 (highest density) breast tissue, the corresponding sensitivity rates of MRI were 88%, 79%, and 92%, respectively.
The histology of the cancer did not influence the detection rate of intraductal components with MRI: sensitivity was 85% in ductal tumors, 83% in lobular tumors, and 87% in ductal-lobular tumors.
Tumor grade also did not influence the sensitivity of MRI: sensitivity was 82% in non-high-grade invasive tumors and 86% in high-grade invasive tumors.
"There were no subgroups that did not profit from preoperative breast MRI for diagnosing intraductal components," said Dr Schrading.
Other subgroups examined were based on age, familial risk of breast cancer, and personal history of breast cancer.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More